DM
CDTX

Deerfield Management’s Cidara Therapeutics CDTX Stock Holding History

Deerfield Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,439
Closed -$873K – 107
2016
Q1 		$873K Sell
3,439
-2,534
-42% -$584K 0.04% 97
2015
Q4 		$2.05M Sell
5,973
-5,906
-50% -$1.77M 0.08% 98
2015
Q3 		$3.02M Hold
11,879
– – 0.12% 104
2015
Q2 		$3.33M Buy
+11,879
New +$3.65M 0.11% 103

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Deerfield Management's CDTX Position: Q2 2016 in Review

Deerfield Management sold out of Cidara Therapeutics (CDTX) in Q2 2016, closing a stake of 3,439 shares — an estimated $873K sold.

Deerfield Management first reported a position in CDTX in Q2 2015 and held it in 4 quarters. The position peaked at $3.33M in Q2 2015. 55 funds tracked by Wall St. Rank hold CDTX as of Q2 2016.

  • Deerfield Management reported no remaining Cidara Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Deerfield Management sold 3,439 Cidara Therapeutics shares in Q2 2016, an estimated $873K.
  • Deerfield Management first reported a position in Cidara Therapeutics in Q2 2015 and held it in 4 quarters.
  • Deerfield Management's Cidara Therapeutics position peaked at $3.33M in Q2 2015.
  • 55 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2016.

Based on Deerfield Management's 13F filing for Q2 2016, filed 15 Aug 2016.